|
US6346614B1
(en)
*
|
1992-07-23 |
2002-02-12 |
Hybridon, Inc. |
Hybrid oligonucleotide phosphorothioates
|
|
ES2300257T3
(es)
|
1999-02-26 |
2008-06-16 |
The University Of British Columbia |
Terapia antisentido contra trpm-2.
|
|
US7569551B2
(en)
|
2000-02-25 |
2009-08-04 |
The University Of British Columbia |
Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
|
|
PT1309726E
(pt)
|
2000-03-30 |
2010-03-08 |
Whitehead Biomedical Inst |
Mediadores de interferência por rna específicos de sequência de rna
|
|
EP1191097A1
(en)
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induction of exon skipping in eukaryotic cells
|
|
KR100909681B1
(ko)
|
2000-12-01 |
2009-07-29 |
막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. |
Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
|
|
JP4491240B2
(ja)
*
|
2002-01-17 |
2010-06-30 |
ザ ユニバーシティ オブ ブリティッシュ コロンビア |
Ｉｇｆｂｐ−２およびｉｇｆｂｐ−５を阻害する二重特異性アンチセンスオリゴヌクレオチド、並びにこれらの使用方法
|
|
AU2003225410A1
(en)
|
2003-03-21 |
2004-10-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
WO2005030260A1
(en)
*
|
2003-10-01 |
2005-04-07 |
The University Of British Columbia |
Bispecific oligonucleotide for the treatment of cns malignancies
|
|
KR101147147B1
(ko)
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
|
WO2005094899A1
(en)
|
2004-04-02 |
2005-10-13 |
The University Of British Columbia |
Clusterin antisense therapy for treatment of cancer
|
|
SI2206781T1
(sl)
|
2004-06-28 |
2016-05-31 |
The University Of Western Australia |
Protismiselni oligonukleotidi za induciranje preskakovanja eksona in postopki njihove uporabe
|
|
USRE48960E1
(en)
|
2004-06-28 |
2022-03-08 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
|
US7923206B2
(en)
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Method of determining a cellular response to a biological agent
|
|
US7923207B2
(en)
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing pools
|
|
US7935811B2
(en)
|
2004-11-22 |
2011-05-03 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing compositions
|
|
WO2006056054A1
(en)
*
|
2004-11-23 |
2006-06-01 |
The University Of British Columbia |
Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels
|
|
CN103301475B
(zh)
|
2005-12-28 |
2016-08-03 |
斯克里普斯研究所 |
药物组合物和表达载体以及调节基因表达的方法和核酸分子的应用
|
|
WO2007123391A1
(en)
|
2006-04-20 |
2007-11-01 |
Academisch Ziekenhuis Leiden |
Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
|
|
EP1857548A1
(en)
|
2006-05-19 |
2007-11-21 |
Academisch Ziekenhuis Leiden |
Means and method for inducing exon-skipping
|
|
WO2007139943A2
(en)
*
|
2006-05-26 |
2007-12-06 |
Ico Therapeutics Inc. |
Therapeutic drug combinations and delivery systems comprising c-raf kinase antisense polynucleotides for treating ocular diseases and disorders
|
|
JP6047270B2
(ja)
|
2006-08-11 |
2016-12-21 |
バイオマリン テクノロジーズ ベー．フェー． |
Ｄｎａリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段
|
|
WO2008036841A2
(en)
|
2006-09-22 |
2008-03-27 |
Dharmacon, Inc. |
Tripartite oligonucleotide complexes and methods for gene silencing by rna interference
|
|
JP5706157B2
(ja)
|
2007-07-12 |
2015-04-22 |
プロセンサ テクノロジーズ ビー．ブイ．Ｐｒｏｓｅｎｓａ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｂ．Ｖ． |
化合物を種々の選択臓器又は組織に標的化するための分子
|
|
DK2203173T3
(en)
|
2007-10-26 |
2016-02-29 |
Academisch Ziekenhuis Leiden |
Materials and methods for prevention of muscle diseases
|
|
USRE48468E1
(en)
|
2007-10-26 |
2021-03-16 |
Biomarin Technologies B.V. |
Means and methods for counteracting muscle disorders
|
|
EP2249874A1
(en)
|
2008-02-08 |
2010-11-17 |
ProSensa Holding BV |
Methods and means for treating dna repeat instability associated genetic disorders
|
|
US8188060B2
(en)
|
2008-02-11 |
2012-05-29 |
Dharmacon, Inc. |
Duplex oligonucleotides with enhanced functionality in gene regulation
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
CA2739464C
(en)
|
2008-10-03 |
2020-03-31 |
Curna, Inc. |
Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
|
|
EP2762567B1
(en)
|
2008-10-24 |
2016-07-13 |
Sarepta Therapeutics, Inc. |
Multiple exon skipping compositions for DMD
|
|
AU2009308217B2
(en)
*
|
2008-10-24 |
2016-01-21 |
Ionis Pharmaceuticals, Inc. |
5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
|
|
KR101829469B1
(ko)
|
2008-12-04 |
2018-03-30 |
큐알엔에이, 인크. |
Ｅｐｏ에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(ｅｐｏ) 관련된 질환의 치료
|
|
RU2569182C2
(ru)
|
2008-12-04 |
2015-11-20 |
КьюРНА,Инк.,US |
Лечение заболеваний, связанных с фактором роста эндотелия сосудов (vegf), посредством ингибирования природного антисмыслового транскрипта к vegf
|
|
KR101866152B1
(ko)
|
2008-12-04 |
2018-06-08 |
큐알엔에이, 인크. |
종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
|
|
KR101682735B1
(ko)
|
2009-02-12 |
2016-12-06 |
큐알엔에이, 인크. |
뇌 유래된 신경영양성 인자 (ｂｄｎｆ)에 대한 자연 안티센스 전사체의 저해에 의한 뇌 유래된 신경영양성 인자 (ｂｄｎｆ) 관련된 질환의 치료
|
|
MX2011009751A
(es)
|
2009-03-16 |
2011-09-29 |
Opko Curna Llc |
Tratamiento de enfermedades relacionadas con factor nuclear (eritroide derivado 2) tipo 2 (nrf2) por inhibicion del transcrito antisentido natural a nrf2.
|
|
JP5904935B2
(ja)
|
2009-03-17 |
2016-04-20 |
クルナ・インコーポレーテッド |
デルタ様１ホモログ（ｄｌｋ１）に対する天然アンチセンス転写物の抑制によるｄｌｋ１関連疾患の治療
|
|
ES2593836T3
(es)
|
2009-04-24 |
2016-12-13 |
Biomarin Technologies B.V. |
Oligonucleótido que comprende una inosina para tratar la DMD
|
|
JP6250930B2
(ja)
|
2009-05-06 |
2017-12-20 |
クルナ・インコーポレーテッド |
トリステトラプロリン（ｔｔｐ）に対する天然アンチセンス転写物の抑制によるｔｔｐ関連疾患の治療
|
|
CN102459596B
(zh)
|
2009-05-06 |
2016-09-07 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
|
CA2761248C
(en)
|
2009-05-08 |
2023-03-14 |
Joseph Collard |
Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
|
|
JP5922017B2
(ja)
|
2009-05-18 |
2016-05-24 |
クルナ・インコーポレーテッド |
リプログラミング因子に対する天然アンチセンス転写物の抑制によるリプログラミング因子関連疾患の治療
|
|
EP2432882B1
(en)
|
2009-05-22 |
2019-12-25 |
CuRNA, Inc. |
TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
|
|
WO2010138806A2
(en)
|
2009-05-28 |
2010-12-02 |
Curna, Inc. |
Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
|
|
JP6128846B2
(ja)
|
2009-06-16 |
2017-05-17 |
クルナ・インコーポレーテッド |
パラオキソナーゼ（ｐｏｎ１）に対する天然アンチセンス転写物の抑制によるｐｏｎ１遺伝子関連疾患の治療
|
|
JP5944311B2
(ja)
|
2009-06-16 |
2016-07-05 |
クルナ・インコーポレーテッド |
コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療
|
|
EP2446036B1
(en)
|
2009-06-24 |
2017-03-01 |
CuRNA, Inc. |
Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
|
|
US8921330B2
(en)
|
2009-06-26 |
2014-12-30 |
Curna, Inc. |
Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
|
|
WO2011005779A2
(en)
|
2009-07-07 |
2011-01-13 |
University Of Southern California |
Biomarkers for the early detection of autoimmune diseases
|
|
WO2011011700A2
(en)
|
2009-07-24 |
2011-01-27 |
Curna, Inc. |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
|
ES2585360T3
(es)
|
2009-08-05 |
2016-10-05 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con un gen de la insulina (INS) por inhibición de la transcripción antisentido natural en un gen de la insulina (INS)
|
|
JP6189594B2
(ja)
|
2009-08-11 |
2017-08-30 |
クルナ・インコーポレーテッド |
アディポネクチン（ａｄｉｐｏｑ）に対する天然アンチセンス転写物の抑制によるアディポネクチン（ａｄｉｐｏｑ）関連疾患の治療
|
|
CN102482670B
(zh)
|
2009-08-21 |
2018-06-15 |
库尔纳公司 |
通过抑制‘hsp70-相互作用蛋白的c末端’(chip)的天然反义转录物而治疗chip相关疾病
|
|
KR101892760B1
(ko)
|
2009-08-25 |
2018-08-28 |
큐알엔에이, 인크. |
ＩＱＧＡＰ에 대한 천연 안티센스 전사체의 억제에 의한 ＧＴＰａｓｅ 활성화 단백질을 함유하는 ＩＱ 모티프(ＩＱＧＡＰ)와 관련된 질환의 치료
|
|
ES2664591T3
(es)
|
2009-09-25 |
2018-04-20 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la filagrina (flg) mediante la modulación de la expresión y actividad del gen FLG
|
|
SMT201800579T1
(it)
|
2009-11-12 |
2019-01-11 |
Univ Western Australia |
Molecole antisenso e metodi per trattare patologie
|
|
CN102712927B
(zh)
|
2009-12-16 |
2017-12-01 |
库尔纳公司 |
通过抑制膜结合转录因子肽酶，位点1(mbtps1)的天然反义转录物来治疗mbtps1相关疾病
|
|
KR101891352B1
(ko)
|
2009-12-23 |
2018-08-24 |
큐알엔에이, 인크. |
간세포 성장 인자(ｈｇｆ)에 대한 천연 안티센스 전사체의 억제에 의한 ｈｇｆ 관련 질환의 치료
|
|
JP6031356B2
(ja)
|
2009-12-23 |
2016-11-24 |
カッパーアールエヌエー，インコーポレイテッド |
Ｕｃｐ２に対する天然アンチセンス転写産物の阻害による脱共役タンパク質２（ｕｃｐ２）関連疾患の治療
|
|
CA2785177C
(en)
|
2009-12-29 |
2019-09-24 |
Curna, Inc. |
Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
|
|
KR101838305B1
(ko)
|
2009-12-29 |
2018-03-13 |
큐알엔에이, 인크. |
ＮＲＦ1(Ｎｕｃｌｅａｒ Ｒｅｓｐｉｒａｔｏｒｙ Ｆａｃｔｏｒ 1)에 대한 천연 안티센스 전사체의 억제에 의한 핵 호흡 인자 1 관련된 질환의 치료
|
|
CN102791862B
(zh)
|
2009-12-31 |
2017-04-05 |
库尔纳公司 |
通过抑制胰岛素受体底物2(irs2)和转录因子e3(tfe3)的天然反义转录物而治疗irs2相关疾病
|
|
JP5886757B2
(ja)
|
2010-01-04 |
2016-03-16 |
カッパーアールエヌエー，インコーポレイテッド |
インターフェロン調節因子８（ｉｒｆ８）に対する天然アンチセンス転写物の阻害によるインターフェロン調節因子８（ｉｒｆ８）関連疾患の治療
|
|
EP2521785B1
(en)
|
2010-01-06 |
2022-03-09 |
CuRNA, Inc. |
Inhibition of natural antisense transcript to a pancreatic developmental gene for use in a treatment of pancreatic developmental gene related diseases
|
|
JP6027893B2
(ja)
|
2010-01-11 |
2016-11-16 |
カッパーアールエヌエー，インコーポレイテッド |
性ホルモン結合グロブリン（ｓｈｂｇ）に対する天然アンチセンス転写物の阻害による性ホルモン結合グロブリン（ｓｈｂｇ）関連疾患の治療
|
|
EP2529015B1
(en)
|
2010-01-25 |
2017-11-15 |
CuRNA, Inc. |
Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
|
|
KR101838308B1
(ko)
|
2010-02-22 |
2018-03-13 |
큐알엔에이, 인크. |
피롤린-5-카르복실레이트 환원효소 1(ｐｙｃｒ1)에 대한 천연 안티센스 전사체의 억제에 의한 ｐｙｃｒ1과 관련된 질환의 치료
|
|
CA2787673A1
(en)
|
2010-03-01 |
2011-09-09 |
Tau Therapeutics Llc |
Cancer diagnosis and imaging
|
|
WO2011112516A1
(en)
*
|
2010-03-08 |
2011-09-15 |
Ico Therapeutics Inc. |
Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
|
|
CA2795145C
(en)
|
2010-04-02 |
2019-01-22 |
Curna, Inc. |
Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
|
|
TWI644675B
(zh)
|
2010-04-09 |
2018-12-21 |
可娜公司 |
藉由抑制纖維母細胞生長因子２１（ｆｇｆ２１）之天然反義轉錄物以治療ｆｇｆ２１相關疾病
|
|
RU2693462C2
(ru)
|
2010-05-03 |
2019-07-03 |
Курна, Инк. |
Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
|
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
|
|
EP2576783B1
(en)
|
2010-05-26 |
2017-11-29 |
CuRNA, Inc. |
Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
|
|
EP2576784B1
(en)
|
2010-05-26 |
2017-11-15 |
CuRNA, Inc. |
Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
|
|
KR102008708B1
(ko)
|
2010-06-23 |
2019-08-08 |
큐알엔에이, 인크. |
전압 작동 나트륨 통로, 알파 소단위(scna)에 대한 자연 안티센스 전사체의 저해에 의한 전압 작동 나트륨 통로, 알파 소단위(scna) 관련된 질환의 치료
|
|
CA2805318A1
(en)
|
2010-07-14 |
2012-01-19 |
Curna, Inc. |
Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
|
|
ES2640755T3
(es)
|
2010-10-06 |
2017-11-06 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la Sialidasa 4 (neu4) mediante inhibición del transcrito antisentido natural al gen neu4
|
|
US9222088B2
(en)
|
2010-10-22 |
2015-12-29 |
Curna, Inc. |
Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
|
|
US9920317B2
(en)
|
2010-11-12 |
2018-03-20 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
|
AU2011325956B2
(en)
|
2010-11-12 |
2016-07-14 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
|
US10000752B2
(en)
|
2010-11-18 |
2018-06-19 |
Curna, Inc. |
Antagonat compositions and methods of use
|
|
EP2643463B1
(en)
|
2010-11-23 |
2017-09-27 |
CuRNA, Inc. |
Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
|
|
JP6188686B2
(ja)
|
2011-06-09 |
2017-08-30 |
カッパーアールエヌエー，インコーポレイテッド |
フラタキシン（ｆｘｎ）への天然アンチセンス転写物の阻害によるｆｘｎ関連疾患の治療
|
|
BR112014005234A2
(pt)
|
2011-09-06 |
2017-04-11 |
Curna Inc |
tratamento de doenças relacionadas com subunididades alfa dos canais de sódio dependentes de voltagem (scnxa) com pequenas moléculas
|
|
CA2848311A1
(en)
|
2011-09-12 |
2013-03-21 |
Tau Therapeutics Llc |
Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells
|
|
US9580708B2
(en)
|
2011-09-14 |
2017-02-28 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotides compounds
|
|
ES2907250T3
(es)
|
2012-01-27 |
2022-04-22 |
Biomarin Tech Bv |
Oligonucleótidos de modulación de ARN con características mejoradas para el tratamiento de la distrofia muscular de Duchenne y de Becker
|
|
HUE040179T2
(hu)
|
2012-03-15 |
2019-02-28 |
Curna Inc |
Agyi eredetû neutrotróf faktorral (Brain-derived neurotrophic factor, BDNF) összefüggõ betegségek kezelése a BDNF-fel kapcsolatos természetes antiszensz transzkriptumok gátlása révén
|
|
AU2013262709A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating MECP2 expression
|
|
CA2873769A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics Inc. |
Compositions and methods for modulating hemoglobin gene family expression
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
BR112014028644A2
(pt)
|
2012-05-16 |
2017-08-15 |
Rana Therapeutics Inc |
Composições e métodos para modulação da expressão de atp2a2
|
|
BR112014028634A2
(pt)
|
2012-05-16 |
2017-06-27 |
Rana Therapeutics Inc |
composições e métodos para modulação da expressão de utrn
|
|
SG11201407483YA
(en)
|
2012-05-16 |
2014-12-30 |
Rana Therapeutics Inc |
Compositions and methods for modulating smn gene family expression
|
|
EP2895200B1
(en)
|
2012-09-14 |
2019-11-06 |
Translate Bio MA, Inc. |
Multimeric oligonucleotide compounds
|
|
US10024844B2
(en)
|
2012-12-20 |
2018-07-17 |
Hospital For Special Surgery |
Identification of an inhibitor of iRhom1 or an inhibitor of iRhom2
|
|
AU2014236140B2
(en)
|
2013-03-14 |
2019-10-03 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for treating muscular dystrophy
|
|
NZ732507A
(en)
|
2013-03-15 |
2018-08-31 |
Sarepta Therapeutics Inc |
Improved compositions for treating muscular dystrophy
|
|
JP2016531570A
(ja)
|
2013-08-16 |
2016-10-13 |
ラナ セラピューティクス インコーポレイテッド |
ユークロマチン領域を標的とするオリゴヌクレオチド
|
|
ES2894333T3
(es)
|
2013-09-26 |
2022-02-14 |
Beth Israel Deaconess Medical Ct Inc |
Inhibidores de SGK1 en el tratamiento del síndrome de QT Largo
|
|
US10272058B2
(en)
|
2014-03-20 |
2019-04-30 |
Cymabay Therapeutics, Inc. |
Treatment of intrahepatic cholestatic diseases
|
|
DK3119384T3
(en)
|
2014-03-20 |
2018-12-03 |
Cymabay Therapeutics Inc |
TREATMENT OF INTRAHEPATHIC COLESTASTIC DISEASES
|
|
UA121208C2
(uk)
|
2014-04-11 |
2020-04-27 |
Сімабей Терапьютікс, Інк. |
Лікування нажхп та насг
|
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
|
AU2015327836B2
(en)
|
2014-10-03 |
2021-07-01 |
Cold Spring Harbor Laboratory |
Targeted augmentation of nuclear gene output
|
|
WO2016070060A1
(en)
|
2014-10-30 |
2016-05-06 |
The General Hospital Corporation |
Methods for modulating atrx-dependent gene repression
|
|
EP3256591A4
(en)
|
2015-02-13 |
2018-08-08 |
Translate Bio Ma, Inc. |
Hybrid oligonucleotides and uses thereof
|
|
EP3271460A4
(en)
|
2015-03-17 |
2019-03-13 |
The General Hospital Corporation |
RNA INTERACTOM OF POLYCOMB REPRESSIVE COMPLEX 1 (PRC1)
|
|
CN108603230A
(zh)
|
2015-10-09 |
2018-09-28 |
南安普敦大学 |
基因表达的调节与蛋白质表达失调的筛选
|
|
WO2017070680A1
(en)
|
2015-10-22 |
2017-04-27 |
Cavion Llc |
Methods for treating angelman syndrome and related disorders
|
|
EP3390636B1
(en)
|
2015-12-14 |
2021-05-19 |
Cold Spring Harbor Laboratory |
Antisense oligomers for treatment of dravet syndrome
|
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
|
JOP20200228A1
(ar)
|
2015-12-21 |
2017-06-16 |
Novartis Ag |
تركيبات وطرق لخفض تعبير البروتين tau
|
|
CN110545806A
(zh)
|
2017-02-15 |
2019-12-06 |
卡维昂公司 |
钙通道抑制剂
|
|
US11324733B2
(en)
|
2017-04-26 |
2022-05-10 |
Cavion, Inc. |
Methods for improving memory and cognition and for treating memory and cognitive disorders
|
|
CN107460219B
(zh)
*
|
2017-07-24 |
2020-04-10 |
武汉大学 |
一种差异核酸酶切方法及其在LC-MS法检测mRNA内部修饰中的应用
|
|
EP3673080B1
(en)
|
2017-08-25 |
2023-10-18 |
Stoke Therapeutics, Inc. |
Antisense oligomers for treatment of conditions and diseases
|
|
JP2021523227A
(ja)
|
2018-05-04 |
2021-09-02 |
ストーク セラピューティクス，インク． |
コレステリルエステル蓄積症の処置のための方法及び組成物
|
|
TWI879741B
(zh)
|
2018-10-03 |
2025-04-11 |
美商卡凡恩公司 |
以(r)-2-(4-異丙基苯基)-n-(1-(5-(2,2,2-三氟乙氧基)吡啶-2-基)乙基)乙醯胺治療自發性震顫
|
|
CN113748209A
(zh)
|
2019-02-27 |
2021-12-03 |
斯托克制药公司 |
用于治疗病况和疾病的反义寡聚体
|
|
AU2021270720A1
(en)
|
2020-05-11 |
2022-12-08 |
Stoke Therapeutics, Inc. |
OPA1 antisense oligomers for treatment of conditions and diseases
|